vimarsana.com
Home
Live Updates
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimers Disease Program | Region : vimarsana.com
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease Program | Region
The Phase II clinical trial in patients with Alzheimer’s disease with neuroinflammation is on track to complete enrollment mid-2024 with top line data expected approximately six months after the final
Related Keywords
Canada ,
Florida ,
United States ,
Jason Nelson ,
David Moss ,
Inmune Bio ,
Nasdaq ,
Drug Administration ,
Inmune Bio Inc ,
Company Annual Report On Form ,
Company Quarterly Reports On Form ,
Globe Newswire Inmune Bio Inc ,
Company Current Reports On Form ,
Exchange Commission ,
Pacific Rim ,
Dominant Negative Tumor Necrosis Factor ,
Early Alzheimer ,
Natural Killer Cell Priming Platform ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Reports ,
Current Reports ,
Bio Contact ,
Region ,
vimarsana.com © 2020. All Rights Reserved.